Overview

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Status:
Active, not recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

A randomised, double blind, parallel group, multicentre study to compare the pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) versus MabThera® in patients with rheumatoid arthritis.

Phase:

Phase 1

Details

Lead Sponsor:

Mabscale, LLC

Treatments:

Rituximab